Molecular Templates, Takeda Strike MM Deal American Cancer Society, Business, Cancer Cells, CD38 Proteins, Collaborations, Deals, Engineered Toxin Bodies (ETBs), Immune System, Immunotoxins, Multiple Myeloma, Multiple Myeloma Cells, Shares Shares of Molecular Templates were up more than 52 percent after announcing a deal with Takeda that could be worth up to $632 million to develop CD38-targeted engineered toxin bodies. Read more September 20, 2018/by BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png 0 0 BioSpace https://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.png BioSpace2018-09-20 12:20:172018-09-20 13:00:26Molecular Templates, Takeda Strike MM Deal